目的 研究曲美布汀联合氯波必利治疗功能性消化不良的疗效。方法 选择2016年1月—2018年12月杨凌示范区医院的82例功能性消化不良患者作为研究对象，用抽签法随机将患者分为对照组和观察组，每组各41例。对照组服用苹果酸氯波必利片，1片/次，3次/d。观察组在对照组的基础上饭后服用马来酸曲美布汀片，0.2 g/次，3次/d。两组均连续治疗2周。观察两组患者的临床治疗效果、症状改善情况及胃动力学相关指标。结果 治疗后，观察组的总有效率为92.68%，明显高于对照组的73.17%（P<0.05）。治疗后，观察组的腹部疼痛感、饱胀不适感、反酸、呕吐及恶心等症状的改善时间明显短于对照组（P<0.05）。治疗后，两组的胃窦收缩频率、胃窦收缩幅度以及胃窦面积的收缩幅度均明显升高，胃半排空时间明显缩短（P<0.05），且观察组胃动力学指标改善更为明显（P<0.05）。治疗后，两组的腹胀、上腹痛、早饱、厌食、暖气、烧心、恶心呕吐、反酸评分均明显降低（P<0.05），且观察组症状评分明显低于对照组（P<0.05）。结论 曲美布汀联合氯波必利治疗功能性消化不良具有确切的疗效，能改善其症状和胃动力学，具有临床推广应用价值。

Objective To study the effect of trimebutine combined with clebopride in treatment of functional dyspepsia. Methods A total of 82 patients with functional dyspepsia in Yangling Demonstration Zone Hospital from January 2016 to December 2018 were selected as research objects, and randomly divided into control group and observation group, with 41 patients in each group. Patients in the control group were po administered with Clebopride Malate Tablets, 1 tablet/time, three times daily. Patients in the control group were po administered with Trimebutine Maleate Tablets on the basis of control group, 0.2 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical therapeutic effect, symptom improvement, and gastric dynamics in two groups were observed. Results After treatment, the total effective rate of the observation group was 92.68%, which was significantly higher than 73.17% of the control group (P<0.05). After treatment, the improvement time of abdominal pain, fullness and discomfort, acid reflux, vomiting and nausea in the observation group was significantly shorter than those in the control group (P<0.05). After treatment, the gastric antrum contraction frequency, the gastric antrum contraction amplitude, and the gastric antrum area in two groups were significantly increased, and the gastric half-emptying time was significantly shortened (P<0.05). And the gastric dynamics indexes in the observation group was significantly improved (P<0.05). After treatment, the scores of abdominal distension, upper abdominal pain, early satiety, anorexia, nausea and vomiting, and acid reflux were significantly reduced in two groups (P<0.05), and the score of symptoms in the observation group was significantly lower than those in the control group (P<0.05). Conclusion Trimebutine combined with clebopride in treatment of functional dyspepsia has definite curative effect, can improve its symptoms and gastric dynamics, and has clinical application value.

R975